{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:23:42Z","timestamp":1773415422007,"version":"3.50.1"},"posted":{"date-parts":[[2025,5,23]]},"group-title":"HIV\/AIDS","reference-count":41,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Since July 2019, the World Health Organization (WHO) has recommended dolutegravir (DTG)-based regimens as preferred first-line antiretroviral therapy (ART) for adults and adolescents living with HIV (DTG-for-All), a reversal of a 2018 safety alert on use of DTG-based regimens by women of reproductive age (WRA). We examined sex and age disparities in DTG uptake before and after DTG-for-All in the International epidemiology Databases to Evaluate AIDS (IeDEA).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We included patients \u226516 years on or initiating treatment between January 2017 and July 2021 in 14 low- and middle-income countries where initial guidelines on DTG-based regimens for first-line ART either restricted use by WRA or had no such restrictions. We estimated the cumulative incidence of DTG uptake (CI-DTG) by sex and age group (aged 16-49 years vs. 50+ years), stratified by patient, clinic and setting characteristics.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 177,706 patients on ART during the study period, 51% were females aged 16-49 years, with 25% males aged 16-49, and 13% and 11%, respectively, females and males aged 50+. At the time of DTG-for-All, overall CI-DTG was 29.6% (95%CI: 29.4, 29.8); it was lower among females aged 16-49 (16.2%; 95%CI: 16.0-16.5) than males (41.1%; 95%CI: 40.6, 41.5), with no sex disparities among patients aged 50+ (females: 46.0%; males: 47.0%). While DTG uptake subsequently increased among all groups, by July 2021, it remained substantially lower among females 16-49 (66.4%; 95%CI: 66.1, 66.7), compared with males 16-49 and older females and males (75.8% to 77.5%). Concentrated in countries where initial guidelines on DTG restricted use by WRA, disparities in DTG uptake persisted at all health system levels and in both low-income and lower-middle income countries.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>While sex-age differentials in DTG uptake narrowed after WHO\u2019s DTG-for-All recommendation, lingering disparities uptake underscore the challenges of policy de-implementation when new evidence emerges.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Key Messages<\/jats:title>\n                  <jats:sec>\n                    <jats:title>What is already known on this topic<\/jats:title>\n                    <jats:p>Prior research illuminated substantial sex and age group disparities in uptake of dolutegravir (DTG)-based antiretroviral therapy (ART) regimens among people with HIV (PLHIV)\u2014disparities that emerged after the World Health Organization (WHO) issued a May 2018 drug safety alert for women of reproductive age (WRA) and persisted after subsequent guidance in July 2019 recommending DTG-based regimens as preferred first-line treatment for all adults and adolescents, irrespective of age and sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>What this study adds<\/jats:title>\n                    <jats:p>Drawing on real-world service delivery data from 72 clinics in 14 countries, this study documents the persistence of sex and age group disparities in DTG-based regimen uptake. Concentrated in low- and lower-middle income countries where national guidelines initially contained restrictions on use of DTG by WRA, these disparities remained substantial at two and three years after WHO\u2019s \u201cdolutegravir for all\u201d guidance among treatment-na\u00efve and treatment-experienced PLHIV and were observed at all health system levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>How this study might affect research, practice or policy<\/jats:title>\n                    <jats:p>Our study underscores the substantial lags that can occur in updating, disseminating, and translating new policy guidance into practice, as well as the challenges of de-implementing outdated policy recommendations when new evidence emerges\u2014challenges that will remain relevant with new treatment regimens, such as injectable ART, on the horizon.<\/jats:p>\n                  <\/jats:sec>\n                <\/jats:sec>","DOI":"10.1101\/2025.05.23.25325682","type":"posted-content","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T18:20:10Z","timestamp":1748024410000},"source":"Crossref","is-referenced-by-count":1,"title":["Lingering sex and age disparities in dolutegravir uptake among adults with HIV: A multi-country observational cohort study"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8514-1958","authenticated-orcid":false,"given":"Ellen","family":"Brazier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew L","family":"Romo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ciaranello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Odhiambo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Pujari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gad","family":"Murenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Kasozi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasisopin","family":"Kiertiburanakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique Mahambou","family":"Nsonde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie R.","family":"Muyindike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vohith","family":"Khol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Lelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Lyamuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man Po","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025052600400522000_2025.05.23.25325682v1.1","unstructured":"World Health Organization (WHO). Update of recommendations on first- and second-line antiretroviral regimens Geneva, Switzerland: World Health Organization; 2019 [cited October 15, 2024]. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325892\/WHO-CDS-HIV-19.15-eng.pdf."},{"key":"2025052600400522000_2025.05.23.25325682v1.2","unstructured":"World Health Organization Statement on DTG [press release]. May 18, 2018 2018."},{"key":"2025052600400522000_2025.05.23.25325682v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1807653"},{"key":"2025052600400522000_2025.05.23.25325682v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905230"},{"key":"2025052600400522000_2025.05.23.25325682v1.5","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3358"},{"issue":"2","key":"2025052600400522000_2025.05.23.25325682v1.6","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/S2352-3018(18)30317-5","article-title":"Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study","volume":"6","year":"2019","journal-title":"Lancet HIV"},{"key":"2025052600400522000_2025.05.23.25325682v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31641-6"},{"key":"2025052600400522000_2025.05.23.25325682v1.8","doi-asserted-by":"crossref","unstructured":"Granich R , S. G. HIV Treatment in sub-Saharan Africa: Did bureaucratic headwinds delay access to dolutegravir? OSF PREPRINTS. 2019.","DOI":"10.31219\/osf.io\/uzg7y"},{"key":"2025052600400522000_2025.05.23.25325682v1.9","doi-asserted-by":"publisher","DOI":"10.7326\/M21-3037"},{"key":"2025052600400522000_2025.05.23.25325682v1.10","doi-asserted-by":"crossref","first-page":"100573","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis","volume":"28","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2025052600400522000_2025.05.23.25325682v1.11","unstructured":"IeDEA. International Epidemiologic Databases to Evaluate AIDS Bern, Switzerland: the Institute of Social and Preventive Medicine (ISPM), University of Bern; [cited December 1, 2023]. Available from: https:\/\/www.iedea.org\/."},{"key":"2025052600400522000_2025.05.23.25325682v1.12","doi-asserted-by":"crossref","unstructured":"Duda SN , Musick BS , Davies M-A , Sohn AH , Ledergerber B , Wools-Kaloustian K , et al. The IeDEA Data Exchange Standard: a common data model for global HIV cohort collaboration. medRxiv [Preprint]. 2020:2020.07.22.20159921.","DOI":"10.1101\/2020.07.22.20159921"},{"key":"2025052600400522000_2025.05.23.25325682v1.13","unstructured":"UNAIDS & WHO. Laws and Policies Analytics 2017-2012 [cited October 8 2024]. Available from: https:\/\/lawsandpolicies.unaids.org\/about?lan=en."},{"key":"2025052600400522000_2025.05.23.25325682v1.14","unstructured":"National Center for HIV\/AIDS DaSN. Operational Guidance: Use of Dolutegravir (DTG) for adults and adolescents in Cambodia. 2018 [cited September 24, 2024]. Available from: https:\/\/www.nchads.gov.kh\/documents_post\/operational-guidance-use-of-dolutegravir-dtg-for-adults-and-adolescents-in-cambodia\/."},{"key":"2025052600400522000_2025.05.23.25325682v1.15","unstructured":"Ministry of Health (Kenya). Guidelines on use of antiretroviral drugs for treating and preventing HIV in Kenya 2018 [cited September 24, 2024]. Available from: https:\/\/hivpreventioncoalition.unaids.org\/en\/resources\/guidelines-use-antiretroviral-drugs-treating-and-preventing-hiv-kenya-2018."},{"key":"2025052600400522000_2025.05.23.25325682v1.16","unstructured":"Ministry of Health (Uganda). Consolidated Guidelines for Prevention and Treatment of HIV in Uganda 2018 [cited September 24, 2024]. Available from: http:\/\/library.health.go.ug\/publications\/service-delivery-diseases-control-prevention-communicable-diseases\/hivaids\/consolidated."},{"key":"2025052600400522000_2025.05.23.25325682v1.17","unstructured":"Ministry of Health (Rwanda). Circular on changes in HIV prevention and management guidelines. 2018 [cited September 24, 2024]. Available from: https:\/\/rbc.gov.rw\/fileadmin\/user_upload\/guide\/Circular."},{"key":"2025052600400522000_2025.05.23.25325682v1.18","unstructured":"Ministere de la Sant\u00e9 Publique (Cameroon). Directives Nationales sur la Prise en Charge du VIH 2019 [cited September 24, 2024]. Available from: https:\/\/hivpreventioncoalition.unaids.org\/en\/resources\/national-guidelines-hiv-care."},{"key":"2025052600400522000_2025.05.23.25325682v1.19","unstructured":"Ministry of Health (Vietnam). Guidelines for HIV\/AIDS Treatment and Care Issued together with Decision No. 5456\/QD-BYT. 2019 [cited September 25, 2024]."},{"key":"2025052600400522000_2025.05.23.25325682v1.20","unstructured":"Minist\u00e8re de la Sant\u00e9 Publique (R\u00e9publique D\u00e9mocratique du Congo). Guide de prise en charge integr\u00e9e du VIH en R\u00e9publique D\u00e9mocratique du Congo (draft).. 2019."},{"key":"2025052600400522000_2025.05.23.25325682v1.21","unstructured":"Ministry of Health (Tanzania). National Guidelines for the Management of HIV and AIDS. 2019 [cited September 24, 2024]. Available from: https:\/\/hivpreventioncoalition.unaids.org\/sites\/default\/files\/attachments\/national_guidelines_for_the_management_of_hiv_and_aids_2019.pdf."},{"key":"2025052600400522000_2025.05.23.25325682v1.22","unstructured":"Ministere de la Sante et de la Population (Republic of Congo). Lignes directrices relatives \u00e0 l\u2019utilisation de m\u00e9dicaments antir\u00e9troviraux pour le traitement et la pr\u00e9vention de l\u2019infection \u00e0 VIH au Congo 2019 ["},{"key":"2025052600400522000_2025.05.23.25325682v1.23","unstructured":"Ministry of Health and Family Welfare (India). National Guidelines for HIV Care and Treatment 2021 [cited September 24, 2024]. Available from: https:\/\/naco.gov.in\/sites\/default\/files\/2020-21.pdf."},{"key":"2025052600400522000_2025.05.23.25325682v1.24","unstructured":"Department of Health (Philippines). Tenofovir\/Lamivudine\/Dolutegravir for treatment-naive and treatment-experienced adolescents and adults living with HIV 2021 [cited September 25, 2024]. Available from: https:\/\/hta.dost.gov.ph\/wp-content\/uploads\/2021\/09\/ES_TLD_for_HIV_approved_by_SOH.docx.pdf."},{"key":"2025052600400522000_2025.05.23.25325682v1.25","unstructured":"Department of Disease Control (Thailand). Thailand National Guidelines on HIV\/AIDS Treatment and Prevention 2021 [cited September 25, 2024]. Available from: https:\/\/www.thaiaidssociety.org\/wp-content\/uploads\/2023\/03\/HIV-AIDS-Guideline-2564_2565_ED2.pdf."},{"key":"2025052600400522000_2025.05.23.25325682v1.26","unstructured":"Expert Panel for HIV\/AIDS and STI Prevention (Indonesia). Rekomendasi Panel Ahli Penanggulangan HIV\/AIDS dan IMS Hasil Rapat Daring, Kamis 2 Juli 2020 2020 [cited October 1, 2024]. Available from: https:\/\/hivaids-pimsindonesia.or.id\/."},{"key":"2025052600400522000_2025.05.23.25325682v1.27","unstructured":"World Health Organization (WHO). Women of reproductive age (15-49 years) population (thousands) 2024 [cited October 9, 2024]. Available from: https:\/\/www.who.int\/data\/gho\/indicator-metadata-registry\/imr-details\/women-of-reproductive-age-(15-49-years)-population-(thousands)."},{"key":"2025052600400522000_2025.05.23.25325682v1.28","unstructured":"The World Bank. World Bank list of economies, June 2022 2022 [cited July 11, 2023]. Available from: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"issue":"3","key":"2025052600400522000_2025.05.23.25325682v1.29","first-page":"141","article-title":"An Empirical Transition Matrix for Non-Homogeneous Markov Chains Based on Censored Observations","volume":"5","year":"1978","journal-title":"Scand J Statist"},{"key":"2025052600400522000_2025.05.23.25325682v1.30","doi-asserted-by":"crossref","unstructured":"Shah N , Esber A , Sean Cavanaugh J , Agaba P , Dear N , Iroezindu M , et al. Transitioning women to first-line preferred TLD regimen is lagging in Sub-Saharan Africa. Clin Infect Dis. 2022.","DOI":"10.1093\/cid\/ciac555"},{"key":"2025052600400522000_2025.05.23.25325682v1.31","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae139"},{"issue":"1","key":"2025052600400522000_2025.05.23.25325682v1.32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-8587(24)00270-5","article-title":"Is it time to revisit the recommendations for initiation of menopausal hormone therapy?","volume":"13","year":"2025","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"1","key":"2025052600400522000_2025.05.23.25325682v1.33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13643-019-1111-8","article-title":"Understanding how and why de-implementation works in health and care: research protocol for a realist synthesis of evidence","volume":"8","year":"2019","journal-title":"Syst Rev"},{"issue":"1","key":"2025052600400522000_2025.05.23.25325682v1.34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13012-019-0960-9","article-title":"Unpacking the complexities of de-implementing inappropriate health interventions","volume":"15","year":"2020","journal-title":"Implementation Science"},{"key":"2025052600400522000_2025.05.23.25325682v1.35","unstructured":"PEPFAR. PEPFAR 2019 Country Operational Plan Guidance for all PEPFAR Countries 2019 [cited November 9, 2024]. Available from: https:\/\/www.state.gov\/wp-content\/uploads\/2019\/08\/PEPFAR-Fiscal-Year-2019-Country-Operational-Plan-Guidance.pdf."},{"key":"2025052600400522000_2025.05.23.25325682v1.36","unstructured":"PEPFAR. Regional Operational Plan (West Africa Regional Program): Strategic Direction Summary 2019 [cited November 12, 2024]. Available from: https:\/\/www.state.gov\/wp-content\/uploads\/2019\/09\/West-Africa_ROP19-Strategic-Directional-Summary_public-FINAL.pdf."},{"key":"2025052600400522000_2025.05.23.25325682v1.37","unstructured":"PEPFAR. Asia Region Operational Plan (ROP 2019): Strategic Direction Summary 2019 [cited November 12, 2024]. Available from: https:\/\/www.state.gov\/wp-content\/uploads\/2019\/09\/Asia-Regional_COP19-Strategic-Directional-Summary_public.pdf."},{"key":"2025052600400522000_2025.05.23.25325682v1.38","unstructured":"da Silva J , Vallabhaneni S , Pati R , Chun H , Malati C , Kiesa D , et al., editors. Successful transition to tenofovir\/lamivudine\/dolutegravir (TLD) in PEPFAR-supported countries. AIDS 2022; 2022; Montreal, Canada."},{"key":"2025052600400522000_2025.05.23.25325682v1.39","unstructured":"E. M. Achieving 95-95-95: Implications for Asia and the Pacific region 2021 [cited November 4, 2024]. Available from: https:\/\/www.aidsdatahub.org\/sites\/default\/files\/resource\/2021-sep5-achieving-95-95-95-hiv-treatment-forum.pdf."},{"key":"2025052600400522000_2025.05.23.25325682v1.40","doi-asserted-by":"crossref","unstructured":"Zaniewski E , Skrivankova VW , Brazier E , Avihingsanon A , Cardoso SW , Cesar C , et al. Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics. Aids. 2024.","DOI":"10.1097\/QAD.0000000000004007"},{"key":"2025052600400522000_2025.05.23.25325682v1.41","unstructured":"Medicines Patent Pool (MPP). DOLUTEGRAVIR - ADULT (DTG) licence 2014 [cited October 15, 2024]. Available from: https:\/\/medicinespatentpool.org\/licence-post\/dolutegravir-adult-dtg."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.05.23.25325682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:36:48Z","timestamp":1768509408000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.05.23.25325682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1101\/2025.05.23.25325682","relation":{},"subject":[],"published":{"date-parts":[[2025,5,23]]},"subtype":"preprint"}}